Dr. Philip Arlen to Speak at the Biomarkers & Immuno-Oncology World Congress 2017
Monoclonal Antibodies Targeting Novel Immunogenic Neo-Epitopes for the Treatment of Solid Tumors May 2-4, 2017, Philadelphia Marriott...
19Apr
02Apr
Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research
Rockville, MD, April 2, 2017 - Precision-Biologics Inc.
03Mar
Immuno-Oncology Breakthroughs – Novel Cancer Therapies
Dr. Philip Arlen to Speak at Immuno-Oncology Breakthroughs - Novel Cancer Therapies at the Noblecon...
01Feb
ImmunoTX Summit
Dr. Philip Arlen to Speak at ImmunoTX Summit - The Discovery and Development of Novel...
29Sep
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress
Dr. Philip Arlen to Speak at Biomarkers & Precision Medicine USA Congress - 3-4 October 2016,...
29Sep
Dr. Philip Arlen to Speak at Immune Profiling World Congress
Dr. Philip Arlen to Speak at Immune Profiling World Congress – 11-12 October 2016, Fairmont...
16Jun
Read more...
18Apr
Precision Biologics to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016
New Orleans. LA– April 17, 2016 — Precision Biologics, a clinical stage biotechnology company...
18Mar
NCI Investigators Collaborate with Moonshoot 2020
https://twitter.com/nciresearchctr/status/694520668679962624
21Jan
Precision Biologics Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer Who Failed all Standard Therapy
Over 30% of patients who failed all standard chemo and antibody therapy remain alive after...